“Latest Stem Cells News”

Researchers at Queen Mary, University of London, studied equivalent cells taken from mouse brains. Principal investigator Silvia Marino, Professor of Neuropathology at Queen Mary, University of London, and her team showed that medulloblastomas can grow from a type of brain stem cell and that these cancers are a distinct form of the disease which may require a completely different approach to treatment.

Like a Hole in the Head: Living with a Brain Tumour

A team of researchers from UCL has won a £500,000 grant to develop a synthetic artery that mimics a natural artery – and could revolutionise the treatment of coronary heart disease.

Professor Alexander Seifalian (UCL Surgery and Interventional Science) and Professor George Hamilton (UCL Surgery and Interventional Science & Royal Free Hospital) and their team will use the Wellcome Trust grant to take their work from the laboratory to a pre-clinical trial.

The team has been developing a new nanomaterial with mechanical properties similar to that of human arteries.

The nanomaterial’s inner surface has been modified to attract stem cells from blood circulating inside the body.

It converts these primary cells to endothelial cells, a type of cell that covers the interior of the natural blood vessel and protects it from blockage.

The breakthrough offers hope for sufferers of heart disease who are unable to donate suitable substitute blood vessels for bypass surgery.

Professors Seifalian and Hamilton, experts in nanotechnology, regenerative medicine and vascular surgery, explained: “Coronary heart disease is a condition where one or more blood vessels of the heart become narrowed or blocked. This causes the heart muscle to be starved of oxygen causing damage often leading to a heart attack and muscle death. This interferes with the heart’s ability to pump blood around the body, leading to infirmity and possibly death.

“The current treatment of the disease is to create a new route for blood to circulate, most often by balloon dilatation and stent (stent angioplasty). In many patients however this intervention cannot be performed and in this situation an operation called bypass surgery is needed which can either use substitute blood vessels from another part of the patient or made from a plastic material.

read more: http://www.ucl.ac.uk/news/news-articles/0908/09081101

DaVinci Biosciences LLC, of Costa Mesa, CA, announced today the presentation of their safety and feasibility study demonstrating the administration of autologous bone marrow derived stem cells for the treatment of acute and chronic spinal cord injury at Neuroscience 2009, Society for Neuroscience’s 39th Annual Meeting, to be held at McCormick Convention Center in Chicago, IL. Rafael Gonzalez, Ph.D., Director of Research and Development for DaVinci Biosciences LLC will present the work during the conference on October 20, 2009 and be available to answer questions regarding the study, following his presentation.

“We are excited to share the findings of this study in such a public forum. This study successfully demonstrates not only the safety and feasibility of using autologous adult stem cells for treating spinal cord injuries, but also that the clinical procedure for delivering these cells is safe as well,” said Dr. Gonzalez.

The abstract highlights data from 8 patients that underwent the treatment which used stem cells harvested from the patients’ own bone marrow to side step any immune rejection response, and features the documented evaluations from a 2 year post surgical follow up period. Furthermore, it illustrates new data obtained from 46 patients that participated in the study using stem cells harvested from the patients’ own bone marrow. Magnetic resonance imaging data of the spinal cord, obtained from those who were treated, shows morphological changes within the damaged areas. In addition, this study documents the improved function of bladder control, ASIA motor scoring and Barthel scoring.

“Although this study was successful, we will build upon the results that we have achieved and the methods we have developed to progress into a larger clinical program. Responsibly, but timely developing ways to improve the quality of life for those affected with injuries or diseases, such as spinal cord injury, is the core of our mission and we are optimistic about the opportunity of conducting future studies in the US,” said Dr. Gonzalez.

from http://www.dvbiosciences.com/

MIAMI, Fla. (Ivanhoe Newswire) — Some are calling it the next big frontier in cardiac treatment — injecting stem cells to regenerate the heart. But the experimental procedure means major surgery. Doctors are opening the door for heart patients who want to test the benefits of stem cells — without an operation.

One heart attack behind him, Max Eaton is now struggling with heart failure. He’s hoping stem cells are the answer to heal his ailing heart. “I happened to run into this article, which was the second or third time I heard about this stem cell research, and decided nothing ventured, nothing gained,” Eaton told Ivanhoe.

Instead of surgery, where the chest is opened and stem cells are injected into the heart, Alan W. Helman, M.D., an interventional cardiologist at the University of Miami, delivers the cells through a catheter that’s threaded through the groin. The spiral-shaped needle at the tip is screwed into the heart.

“We can now inject the cells exactly where we want to in the inside part of the heart, and we can do it in multiple different locations,” Joshua Hare, M.D., a cardiologist at the University of Miami, told Ivanhoe.
Doctors say it’s a more efficient way of delivering stem cells (…) Now, Eaton is hoping his wager on stem cells will pay off.

Doctors say Eaton is responding well to his stem cell treatment. All of the stem cells being used in this trial are adult stem cells. Studies have shown injecting heart attack patients with adult stem cells can increase the pumping power of the heart. However, it is not an approved treatment for re-growing heart tissue.

Full-length interview with Dr. Hare

from http://ivanhoe.com/channels/p_channelstory.cfm?storyid=22514

Scientists have taken the first steps toward producing the “heart patch,” a design for a medical implement used to repair damage from heart disease, a new study suggests.

Last week, researchers from Duke University presented the results of a study which, using mouse embryonic stem cells, examined the way these cells develop into heart muscle, HealthDay News reports (…)

from http://www.privatemdlabs.com/news/Heart_Health_and_Cholesterol/Mouse-stem-cell-study-examines-heart-repair$19405309.php

Neuralstem Inc. has received the green light to begin the first human stem cell trial to treat Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig’s disease. The company’s stock soared on the news.

Neuralstem has only received approval for the first stage of the trial that would consist of 12 patients who will receive stem cell injections in the lumbar area of the spinal cord.

Neuralstem said the trial will be under the direction of principal investigator Dr. Eva L. Feldman, Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery. Feldman called the trial a major step forward in the treatment of ALS. “In work with animals, these spinal cord stem cells both protected at-risk motor neurons and made connections to the neurons controlling muscles. We don’t want to raise expectations unduly, but we believe these stem cells could produce similar results in patients with ALS,” Dr. Feldman said.

from

http://washington.bizjournals.com/washington/stories/2009/09/21/daily7.html

http://www.reuters.com/article/americasRegulatoryNews/idUSBNG36053620090921